Clinical content on topics that will help to improve patient care and health outcomes showcased by pharmaceutical companies are a valuable part of the WCP 2017. Apart from the scientific programme exhibiting companies are hosting several Industry Symposia.
|
Pushing back frontiers in neuropsychiatric disease therapy (Dr. Willmar Schwabe GmbH & Co. KG) |
|
|
Chair: |
|
| Speaker: Hans-Peter Volz, Germany |
Anxiety therapy: Closing the gap between efficacy and safety |
|
Speaker: |
Behavioural and psychological symptoms associated with dementia (BPSD): Prevalence, clinical importance and treatment options |
| Tranylcypromin - effektives und sicheres Management therapieresistenter Depression mit dem Ansatzpunkt Monoaminoxidase (Aristo Pharma GmbH) 11:45 - 13:15 | Hall New York 2 |
|
| Chair: Mazda Adli, Germany |
|
| Speaker: Manfred Gerlach, Germany |
Monoaminoxidase - eine nach wie vor zeitgemäße pharmakologische Zielstruktur der Depressionsbehandlung mit Tranylcypromin |
| Speaker: Roland Ricken, Germany |
Von Fallberichten und kontrollierten Studien zur Meta-Analyse - Tranylcypromin in der Therapie der Depression |
| Speaker: Willem A. Nolen, The Netherlands |
Klinische Pharmakologie und praktische Therapie von Tranylcypromin: besondere Rolle bei atypischer Depression? |
|
Advances in schizophrenia: Why do we need new treatment options? (Otsuka Pharmaceutical Development & Commercialization, Inc & H. Lundbeck A/S) |
|
| Chair: Christoph Correll, USA |
|
| Speaker: Celso Arango, Spain |
Schizophrenia today and what we need tomorrow |
| Speaker: Leslie Citrome, USA |
Pharmacology of the D2 partial agonists - What they bring to the table |
| Speaker: John Kane, USA |
Brexpiprazole for treatment of patients with acute schizophrenia - The short term perspective |
| Speaker: Christoph Correll, USA |
Brexpiprazole for relapse prevention in schizophrenia - The long term view |
| Panel discussion |
|
| Paving the way to remission from depression (SERVIER) 11:45 - 13:15 | Hall A4 |
|
|
Chair: Hans-Jürgen Möller, Germany |
|
| Speaker: Koen Demyttenaere, Belgium |
Meeting the challenge of characterizing depressed patients’ symptoms |
| Speaker: Siegfried Kasper, Austria |
Restoring functioning to achieve remission |
|
Speaker: |
Sharing our patients’ experiences with agomelatine |
| Speaker: Hans-Jürgen Möller, Germany Siegfried Kasper, Austria |
Panel discussion |
| Stimulieren, wenn Medikamente nicht mehr helfen? Neurostimulation als Optionstherapie bei schwerbehandelbaren Depressionen? (LivaNova Deutschland GmbH) 11:45 - 13:15 | Room M8 |
|
|
Chair: |
|
| Speaker: Here W. Folkerts, Germany |
Indikation zur VNS Therapy aus der Perspektive des EKT-Anwenders |
| Speaker: Helge Mueller, Germany |
Vagusnervstimulation – klinische und theoretische Aspekte der psychiatrischen Anwendung |